CCK2 receptor-deficient mice have increased sensitivity of dopamine D2 receptors

Neuropeptides

Volumn 37, Issue 1, 2003, Pages 25-29

  Koks S ^a   Abramov, U ^a   Veraksits A ^a   Bourin, M ^b   Matsui, T ^c   Vasar, E ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITÉ DE NANTES   (France)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT2 receptors; Amphetamine; Apomorphine; CCK2 receptor deficient mice; Dopamine D2 receptors; Locomotor activity

Indexed keywords

AMPHETAMINE; APOMORPHINE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR 2; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; CHOLECYSTOKININ B RECEPTOR; SPIPERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; LOCOMOTION; LOW DRUG DOSE; MALE; MOTOR ACTIVITY; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR SENSITIVITY; WILD TYPE; ANIMAL; BRAIN CORTEX; C57BL MOUSE; DRUG EFFECT; ELECTROPHYSIOLOGY; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; RADIOASSAY; SYNAPTIC TRANSMISSION;

ANIMALS; APOMORPHINE; CEREBRAL CORTEX; DOPAMINE AGONISTS; ELECTROPHYSIOLOGY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; RADIOLIGAND ASSAY; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, DOPAMINE D2; SPIPERONE; SYNAPTIC TRANSMISSION;

EID: 0037645276     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(02)00137-3     Document Type: Article

References (19)

1. Bradbury, A.J., Costall, B., Naylor, R.J., Neumeyer, J.L., 1983. Motor inhibition induced by apomorphine derivatives in the mouse. J. Pharm. Pharmacol. 35, 494-499.
2. Bradford, M.M., 1976. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
3. Costall, B., Domeney, A.M., Naylor, R.J., 1985. The continuity of dopamine receptors antagonism can dictate the long-term consequences of a mesolimbic infusion of dopamine. Neuropharmacology 24, 193-198.
4. Crawley, J.N., 1992. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. J. Neurosci. 12, 3380-3391.
5. Crawley, J.N., Corwin, R.L., 1994. Biological actions of cholecystokinin. Peptides 15, 741-755.
6. Daugé, V., Böhme, G.A., Crawley, J.N., Durieux, C., Stutzmann, J.M., Feger, J., Blanchard, J.C., Roques, B.P., 1990. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCK-B receptors using a new highly potent CCK analog, BC 264. Synapse 6, 73-80.
7. Ferraro, L., O'Connor, W.T., Li, X.M., Rimondini, R., Beani, L., Ungerstedt, U., Fuxe, K., Tanganelli, S., 1996. Evidence for a differential cholecystokinin-B and -A receptor regulation of GABA release in the rat nucleus accumbens mediated via dopaminergic and cholinergic mechanisms. Neuroscience 73, 941-950.
8. Hökfelt, T., Skirboll, L., Rehfeld, J.F., Goldstein, M., Markey, K., Dann, O., 1980. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunochemistry combined with retrograde tracing. Neuroscience 5, 2093-2110.
9. Kopin, A.S., Mathes, W.F., McBride, E.W., Nguyen, M., Al-Haider, W., Schmitz, F., Bonner-Weir, S., Kanarek, R., Beinborn, M., 1999. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J. Clin. Invest. 103, 383-391.
10. Kuczenski, R., 1983. Biochemical actions of amphetamine and other stimulants. In: Creese, I. (Ed.), Stimulants: Neurochemical, Behavioral and Clinical Perspectives. Raven Press, New York, pp. 31-61.
11. Kõks, S., Vasar, E., Soosaar, A., Lang, A., Volke, V., Võikar, V., Bourin, M., Mönnistö, P.T., 1997. Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. Eur. Neuropsychopharmacol. 7, 289-294.
12. Ladurelle, N., Geller, G., Blommaert, A., Roques, B.P., Daugé, V., 1997. The CCK-B agonist, BC 264, increases dopamine in the nucleus and facilitates motivation and attention after intraperitoneal injection in rats. Eur. J. Neurosci. 9, 1804-1814.
13. Meltzer, H.Y., 1980. Relevance of dopamine autoreceptors for psychiatry. Preclinical and clinical studies. Schizophrenia Bull. 3, 456-467.
14. Nagata, A., Ito, M., Iwata, N., Kuno, J., Takano, H., Minowa, O., Chihara, K., Matsui, T., Noda, T., 1996. G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc. Natl. Acad. Sci. 93, 11825-11830.
15. Noble, F., Wank, S.A., Crawley, J.N., Bradwejn, J., Seroogy, K.B., Hamon, M., Roques, B.P., 1999. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol. Rev. 51, 745-781.
16. Rasmussen, K., Czachura, J.F., Stockton, M.E., Howbert, J.J., 1993. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J. Pharmacol. Exp. Ther. 264, 480-488.
17. Sebret, A., Lena, I., Crete, D., Matsui, T., Roques, B.P., Daugé, V., 1999. Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation. J. Neurosci. 19, 7230-7237.
18. Vasar, E., Harro, J., Lang, A., Põld, A., Soosaar, A., 1991. Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse. Psychopharmacology 105, 393-399.
19. B receptor knockout mice: gender related behavioural differences. Eur. Neuropsychopharmacol. 10 (Suppl. 2), S69.